Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

Gastroenterology

Volumn 152, Issue 3, 2017, Pages 598-607.e2

  Park, Charlie C ^a   Nguyen, Phirum ^a   Hernandez, Carolyn ^a   Bettencourt, Ricki ^a   Ramirez, Kimberly ^a   Fortney, Lynda ^a   Hooker, Jonathan ^a   Sy, Ethan ^a   Savides, Michael T ^a   Alquiraish, Mosab H ^a   Valasek, Mark A ^a   Rizo, Emily ^a   Richards, Lisa ^a   Brenner, David ^a   Sirlin, Claude B ^a   Loomba, Rohit ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Assessment; Biomarker; Comparative; Noninvasive

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BILIRUBIN GLUCURONIDE; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; INSULIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FATTY LIVER; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INTERNATIONAL NORMALIZED RATIO; LIVER BIOPSY; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; MALE; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; TRANSIENT ELASTOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL; ADULT; AGED; AREA UNDER THE CURVE; BIOPSY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; ECHOGRAPHY; ELASTOGRAPHY; LIVER; LIVER CIRRHOSIS; MIDDLE AGED; PATHOLOGY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; AREA UNDER CURVE; BIOPSY; CROSS-SECTIONAL STUDIES; ELASTICITY IMAGING TECHNIQUES; FEMALE; HUMANS; LIVER; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PROSPECTIVE STUDIES; ROC CURVE; ULTRASONOGRAPHY;

EID: 85010743428     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.10.026     Document Type: Article

References (51)

1. 1 Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10 (2013), 686–690.
2. 2 Marchesini, G., Brizi, M., Bianchi, G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001), 1844–1850.
3. 3 Williams, C.D., Stengel, J., Asike, M.I., et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140 (2011), 124–131.
4. 4 Neuschwander-Tetri, B.A., Loomba, R., Sanyal, A.J., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385 (2015), 956–965.
5. 5 Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
6. 6 Singh, S., Allen, A.M., Wang, Z., et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 13 (2015), 643–654 e1–e9; quiz e39–e40.
7. 7 Vernon, G., Baranova, A., Younossi, Z.M., Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34 (2011), 274–285.
8. 8 Harrison, S.A., Torgerson, S., Hayashi, P.H., The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol 98 (2003), 2042–2047.
9. 9 Bonekamp, S., Tang, A., Mashhood, A., et al. Spatial distribution of MRI-determined hepatic proton density fat fraction in adults with nonalcoholic fatty liver disease. J Magn Reson Imaging 39 (2014), 1525–1532.
10. 10 Merriman, R.B., Ferrell, L.D., Patti, M.G., et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 44 (2006), 874–880.
11. 11 Ratziu, V., Charlotte, F., Heurtier, A., et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128 (2005), 1898–1906.
12. 12 Sandrin, L., Fourquet, B., Hasquenoph, J.M., et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 29 (2003), 1705–1713.
13. 13 Friedrich-Rust, M., Ong, M.F., Martens, S., et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 134 (2008), 960–974.
14. 14 Wong, V.W., Vergniol, J., Wong, G.L., et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 51 (2010), 454–462.
15. 15 Pavlov, C.S., Casazza, G., Nikolova, D., et al. Systematic review with meta-analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease. Aliment Pharmacol Ther 43 (2016), 575–585.
16. 16 Sasso, M., Beaugrand, M., de Ledinghen, V., et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 36 (2010), 1825–1835.
17. 17 Myers, R.P., Pollett, A., Kirsch, R., et al. Controlled attenuation parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int 32 (2012), 902–910.
18. 18 Chan, W.K., Nik Mustapha, N.R., Mahadeva, S., Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease. J Gastroenterol Hepatol 29 (2014), 1470–1476.
19. 19 de Ledinghen, V., Vergniol, J., Capdepont, M., et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol 60 (2014), 1026–1031.
20. 20 Foucher, J., Castera, L., Bernard, P.H., et al. Prevalence and factors associated with failure of liver stiffness measurement using FibroScan in a prospective study of 2114 examinations. Eur J Gastroenterol Hepatol 18 (2006), 411–412.
21. 21 de Ledinghen, V., Wong, V.W., Vergniol, J., et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan(R). J Hepatol 56 (2012), 833–839.
22. 22 Wong, V.W., Vergniol, J., Wong, G.L., et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 107 (2012), 1862–1871.
23. 23 Huwart, L., Sempoux, C., Vicaut, E., et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 135 (2008), 32–40.
24. 24 Talwalkar, J.A., Elastography for detecting hepatic fibrosis: options and considerations. Gastroenterology 135 (2008), 299–302.
25. 25 Loomba, R., Wolfson, T., Ang, B., et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology 60 (2014), 1920–1928.
26. 26 Cui, J., Ang, B., Haufe, W., et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Aliment Pharmacol Ther 41 (2015), 1271–1280.
27. 27 Cui, J., Heba, E., Hernandez, C., et al. Magnetic resonance elastography is superior to acoustic radiation force impulse for the diagnosis of fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease: a prospective study. Hepatology 63 (2016), 453–461.
28. 28 Permutt, Z., Le, T.A., Peterson, M.R., et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease—MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 36 (2012), 22–29.
29. 29 Tang, A., Desai, A., Hamilton, G., et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology 274 (2015), 416–425.
30. 30 Venkatesh, S.K., Yin, M., Ehman, R.L., Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging 37 (2013), 544–555.
31. 31 Dulai, P.S., Sirlin, C.B., Loomba, R., MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: clinical trials to clinical practice. J Hepatol 65 (2016), 1006–1016.
32. 32 Imajo, K., Kessoku, T., Honda, Y., et al. Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography. Gastroenterology 150 (2016), 626–637 e7.
33. 33 Le, T.A., Chen, J., Changchien, C., et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 56 (2012), 922–932.
34. 34 Loomba, R., Sirlin, C.B., Ang, B., et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial). Hepatology 61 (2015), 1239–1250.
35. 35 Loomba, R., Schork, N., Chen, C.H., et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin study. Gastroenterology 149 (2015), 1784–1793.
36. 36 Doycheva, I., Cui, J., Nguyen, P., et al. Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther 43 (2016), 83–95.
37. 37 Loomba, R., Cui, J., Wolfson, T., et al. Novel 3D magnetic resonance elastography for the noninvasive diagnosis of advanced fibrosis in NAFLD: a prospective study. Am J Gastroenterol 111 (2016), 986–994.
38. 38 Kleiner, D.E., Brunt, E.M., Van Natta, M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005), 1313–1321.
39. 39 Tang, A., Tan, J., Sun, M., et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology 267 (2013), 422–431.
40. 40 Yin, M., Talwalkar, J.A., Glaser, K.J., et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 5 (2007), 1207–1213 e2.
41. 41 Castera, L., Forns, X., Alberti, A., Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48 (2008), 835–847.
42. 42 Youden, W.J., Index for rating diagnostic tests. Cancer 3 (1950), 32–35.
43. 43 DeLong, E.R., DeLong, D.M., Clarke-Pearson, D.L., Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44 (1988), 837–845.
44. 44 Angulo, P., Kleiner, D.E., Dam-Larsen, S., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 149 (2015), 389–397 e10.
45. 45 Cui, J., Philo, L., Nguyen, P., et al. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol 65 (2016), 369–376.
46. 46 Patel, J., Bettencourt, R., Cui, J., et al. Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. Therap Adv Gastroenterol 9 (2016), 692–701.
47. 47 Noureddin, M., Lam, J., Peterson, M.R., et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 58 (2013), 1930–1940.
48. 48 Fraquelli, M., Rigamonti, C., Casazza, G., et al. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 56 (2007), 968–973.
49. 49 Coco, B., Oliveri, F., Maina, A.M., et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 14 (2007), 360–369.
50. 50 Millonig, G., Reimann, F.M., Friedrich, S., et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 48 (2008), 1718–1723.
51. 51 Castera, L., Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 142 (2012), 1293–1302 e4.